Insuffisance tricuspide en 2023 : modalités de traitement pour la valve oubliée [Tricuspid regurgitation in 2023 : Where are we with the treatment of the forgotten valve?]
Fiche du document
8 mars 2023
- doi: 10.53738/REVMED.2023.19.817.477
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2023.19.817.477
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/36883709
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_A9243000285D3
info:eu-repo/semantics/embargoedAccess , Restricted: cannot be viewed until 2024-09-08 , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
TherapyCiter ce document
D. Meier et al., « Insuffisance tricuspide en 2023 : modalités de traitement pour la valve oubliée [Tricuspid regurgitation in 2023 : Where are we with the treatment of the forgotten valve?] », Serveur académique Lausannois, ID : 10.53738/REVMED.2023.19.817.477
Métriques
Partage / Export
Résumé
The negative impact of tricuspid regurgitation on prognosis in now well established. It also appears clear that surgical and possibly percutaneous treatment should be performed before reaching a point of no return with advanced heart failure and deterioration of right ventricle function. Percutaneous treatment has been divided into coaptation restoration devices, annuloplasty devices, and ortho- or heterotopic valve replacement. The present article offers a brief review of diagnostic modalities beyond echocardiography, surgical treatment as well as of the multiple recent development in the percutaneous treatment of this frequent condition.